Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)

Triple negative breast cancer update! We now have the 5 year overall survival data for KEYNOTE 522 trial: adding immunotherapy with pembrolizumab (Keytruda) to chemo for stage 2-3 #TNBC improved survival by 5%. 86.6% of patients who received immunotherapy + #chemotherapy were alive at 5 years vs 81.7% of patients who received chemotherapy alone. More info in the video (including breakdown for pathologic complete response or not).
Watch the video and then let me know your questions!
This was presented at the #ESMO meeting and published in New England Journal of Medicine. #triplenegative #keytruda #immunotherapy #oncologist #cancer